Health-related quality of life questionnaires in lung cancer trials: A systematic literature review by Damm, Kathrin et al.
Damm et al. Health Economics Review 2013, 3:15
http://www.healtheconomicsreview.com/content/3/1/15REVIEW Open AccessHealth-related quality of life questionnaires in
lung cancer trials: a systematic literature review
Kathrin Damm1*, Nicole Roeske1 and Christian Jacob2Abstract
Background: Lung cancer is one of the leading causes of cancer deaths. Treatment goals are the relief of
symptoms and the increase of overall survival. With the rising number of treatment alternatives, the need for
comparable assessments of health-related quality of life (HRQoL) parameters grows. The aim of this paper was to
identify and describe measurement instruments applied in lung cancer patients under drug therapy.
Methods: We conducted a systematic literature review at the beginning of 2011 using the electronic database Pubmed.
Results: A total of 43 studies were included in the review. About 17 different measurement instruments were
identified, including 5 generic, 5 cancer-specific, 4 lung cancer-specific and 3 symptom-specific questionnaires. In 29
studies at least 2 instruments were used. In most cases these were cancer and lung cancer-specific ones. The most
frequently used instruments are the EORTC QLQ-C30 and its lung cancer modules LC13 or LC17. Only 5 studies
combined (lung) cancer-specific questionnaires with generic instruments.
Conclusions: The EORTC-C30 and EORTC-LC13 are the most frequently used health-related quality of life
measurement instruments in pharmacological lung cancer trials.
Keywords: Lung cancer, Health-related quality of life, Questionnaires, Health economics, Utility measurementReview
Introduction
Lung cancer is one of the most frequent cancers in
Germany. With more than 47,000 new cases in 2006,
lung cancer ranks third among malignant tumors; with a
5-year survival rate of about 15% [1]. Symptoms include
cough, coughing up blood, shortness of breath, chronic
lung inflammation, chest pain, weakness or loss of appetite.
Due to a long term symptom-free course of the disease and
non-specific complaints at first, lung cancer in contrast to
other tumours is often diagnosed at an advanced stage.
Therefore, treatment goals for these patients are symptom
relief and an increased overall survival [2]. At the same time
therapies that improve survival time are often accompanied
by burdensome (toxic) side effects.
Because of the increasing number of therapy lines and
treatment alternatives, the declining differences in clinical
effectiveness and cost of drugs, the importance of consist-
ent and comparable health-related quality of life (HRQoL)* Correspondence: kd@ivbl.uni-hannover.de
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in any medium, provided the original work is pparameters grows - both for medical and health economic
evaluation. Up to today, their inclusion in clinical lung
cancer trials is generally neglected [2-4].
The questionnaire-based measurement of HRQoL has
become standard. To assess the HRQoL in patients with
lung cancer, about 50 different instruments are available
that directly address to the patient or apply to the practi-
tioner [4]. In general, criteria used to distinguish the various
instruments are the aggregated or disaggregated scores, or-
dinal measures or cardinal scales and the disease specificity
(see Table 1) [5].
In addition to former research by Liu et al. [3], who
reviewed and summarized HRQoL measures in kidney
cancer, hepatocellular carcinoma, and leukemia, the aim
of this systematic literature review is to investigate which
questionnaires are applied in lung cancer patients treated
with drugs. Using this approach, we examine whether the
variety of possible lung cancer measurement instruments
is also reflected by research practice.
Methods
Research and documentation were carried out in accordance
with the guideline PRISMA (Preferred Reporting Items forn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Classification of HRQoL-questionnaires
Classification of HRQoL-questionnaires
Aggregation of results Disease specificity Scaling
Separate measurement of
different dimensions of HRQoL
Aggregation to
an index
Comparison within
a group of patients
Comparison between
patient groups
Determining a
rank order
Determining relative
distances
Particularly suitable for
medical purposes
Particularly suitable for
economic purposes
Particularly suitable
for medical purposes
Particularly suitable for
economic purposes
Particularly suitable
for medical purposes
Particularly suitable for
economic purposes
Source: Based on Schöffski O (2007) [5].
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the database PubMed combining the following search terms:
“Biological Therapy” (MeSH), “Chemicals and Drugs
Category” (MeSH), “Drug Therapy” (MeSH), “Individualized
Medicine” (MeSH), “Lung Neoplasms” (MeSH), “Outcome
and Process Assessment (Health Care)” (MeSH Major
Topic), “Quality of Life” (MeSH Major Topic), “Symptom
Palliation” (Free text search, Major Topic). The quality of life
associated key words were defined as major topic, to exclude
articles that deal with the issue only as a secondary aspect.
In addition, a manual search was carried out. In order to
focus on current publications, the present review includes
literature published in English and German language
between 2001 and 2011. Titles, abstracts and full-textsPubmed search results
total n = 222
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Figure 1 Flow chart of study selection.of the identified studies were reviewed independently by
three researchers. Exclusion criteria are documented in
Figure 1. The identified studies were analyzed concerning
the HRQoL results and used questionnaires.
Results
A total of 43 studies on the HRQoL measurement in
lung cancer patients treated with drugs were identified
(see Figure 1). The language restriction led only to small
deviations from the overall number of identified studies.
Most of the identified literature presents results of phase
III clinical trials (see Table 2). In 27 studies HRQoL is a
primary endpoint. The majority of studies (n=38) includes
patients with non-small cell lung cancer (NSCLC), mainlytes removed
n = 67
 98
ncer n = 9
eatment n = 12
measurement n = 14
rvey n = 2
ic proof/development of an instrument n = 6
ical paper n = 1
 42
mmentaryn = 12 
14
eatment n = 1
measurement n = 5 
issing data study n = 2
conomic Analyses n = 1
rument/methods at forefront n = 2
ncer specific n= 1 
rt n = 2
Table 2 Identified literature overview
Author (Year) Study, Phasetumor type stadium Treatment outline
HRQoL
endpoints QoL outcome QoL instruments
Agteresch HJ
et al. (2002) [7]
Clinical trial NSCLC IIIB/IV Adenosine 5'-Triphosphate
(ATP) vs. non
secondary No change in appetite and body comparison
in the ATP group. Control group lost weight
and appetite.
Rotterdam Symptom
Checklist (RSCL)
Baka S et al.
(2005) [8]
Clinical trial, II NSCLC IIIB/IV Comparison of two different treatment
schedules for Gemcitabine
primary Significant improvement in performance from
baseline, no sign. difference between
treatment schedules.
Subset Scale from the
EORTC QLQ-C30 and LC13,
Karnofsky performance scale
Belani C et al.
(2006) [9]
Clinical trial, III NSCLC IIIB/
IV
Comparison of two Docetaxel-platinum
regimens with Vinorelbine/Cisplatin
primary Patients treated with Docetaxel-containing
regimen had better QoL and relieved symptoms.
LCSS, EQ-5D
Bezjak A et al.
(2008) [10]
Clinical trial, III NSCLC IB/II Adjuvant chemotherapy
(Cisplatin and Vinorelbine vs. non)
secondary After chemotherapy QoL returned to baseline
by 9 months compared to 3 months in the
control group.
EORTC QLQ-C30
Bezjak A et al.
(2006) [11]
Clinical trial, III NSCLC
advanced
Erlotinib vs. placebo after
prior chemotherapy
secondary Sign. Improvement in physical and global QoL,
dypnea, cough, pain, emotional functioning,
deterioration in sore mouth and hairloss
compared to baseline.
EORTC QLQ-C30,-LC13
Bianco V et al.
(2001) [12]
Clinical trial NSCLC IIIB/IV Gemcitabine as single agent therapy in
advanced NSCLC in elderly patients (>65)
primary Improvement in QoL, reduction of symptoms. Spitzer-Index, Instrumental
Activities of Daily Living Scale
(IADL), EORTC QLQ-C30,-LC13
Booton R et al.
(2006) [13]
Clinical trial, III NSCLC III/IV Docetaxel/Carboplatin vs. Mitomycin
C/Cisplatin/Vinblastine vs.
Ifosfamide/Cisplatin
secondary No superiority of one regimen. Hospital Anxiety and Depression
Scale (HADS), EORTC
QLQ-C30,-LC13
Bozcuk H et al.
(2006) [14]
Clinical trial NSCLC IIIB/IV Examining determinants of a QoL
improvement with chemotherapy in
patients with advanced NSCLC.
primary Age, baseline QoL and chemotherapy
administration influence the degree of
change in QoL.
EORTC QLQ-C30
Brown J et al.
(2005) [15]
Clinical trial NSCLC IV Supportive care with vs. without
additional chemotherapy
primary No sign. difference in QoL. EORTC QLQ-C30,-LC17
Cella D et al.
(2005) [16]
Clinical trial, II NSCLC
advanced
Comparison of two different treatment
dosages Gefitinib in heavily
pretreated patients
primary and
secondary
QoL improvements were correlated with
tumor response.
FACT-L
Chen M.-L.
(2008) [17]
Clinical trial NSCLC
IIIB/IV, SCLC
Examining the impact of sleep
disturbance of lung cancer patients
undergoing chemotherapy on their QoL
primary Sign. impact on the cognitive function
and functional status.
HADS, Pittsburgh Sleep Quality
Index (PSQI), Brief Pain Inventory
(BPI), EORTC QLQ-C30,-LC13
Dancey J et al.
(2004) [18]
Clinical trial, III NSCLC IIIB/
IV
Docetaxel second-line vs. Best
Supportive Care (BSC)
secondary A trend towards less deterioration in QoL
compared to BSC
LCSS EORTC QLQ-C30,-LC13
de Marinis F
et al. (2008) [19]
Clinical trial, III NSCLC III/IV Pemetrexed vs. Docetaxel secondary Positive response on chemotherapy
correlates with symptom improvement.
LCSS
Gelibter A et al.
(2005) [20]
“Compassionate-Use”
NSCLC III/IV
Gefitinib primary Improvements in fatigue, insomnia, and pain,
deterioration in sore mouth, chest-pain, diarrhea.
EORTC QLQ-C30,-LC13
Gridelli C et al.
(2003) [21]
Clinical trial, III NSCLC IIIB/
IV
Gemcitabine/Vinorelbine vs. Gemcitabine/
Cisplatin vs. Vinorelbine/Cisplatin
primary Global QoL is not improved with
Gemcitabine/Vinorelbine.
EORTC QLQ-C30,-LC13
Grønberg BH et al.
(2009) [22]
Clinical trial, III NSCLC IIIB/IV First-line Pemetrexed/Carboplatin
vs. Gemcitabine/Carboplatin
primary Pemetrexed/Carboplatin provides similar
HRQoL with less need for supportive care.
EORTC QLQ-C30,-LC13
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Table 2 Identified literature overview (Continued)
Helbekkmo N et al.
(2009) [23]
Clinical trial, III NSCLC IIIB/IV Carboplatin Chatelut AUC/Vinorelbine
or Carboplatin/Gemcitabine in
patients with a performance status (PS)
2 compared to patients with PS 0/1
primary PS 2 patients had a more profound
improvement of global HRQoL.
EORTC QLQ-C30,-LC13
Hensing TA et al.
(2003) [24]
Clinical trial, III NSCLC IIIB/IV 4 cycles of Carboplatin/Paclitaxel or
until disease progression in patients
younger than age 70 compared to
those aged 70 years and older
primary No difference in QoL outcomes. FACT-L
LeCaer H et al.
(2005) [25]
Clinical trial, II NSCLC IIIB/IV Docetaxel monotherapy in elderly patients primary QoL remained stable during treatment. Spitzer-Index EORTC
QLQ-C30,-LC13
Leighl NB et al.
(2005) [26]
Clinical trial, III NSCLC IIIB/
IV
Paclitaxel/Carboplatin with or
without BMS-275291
secondary No detailed results presented. EORTC QLQ-C30,-LC13
Lilenbaum R et al.
(2007) [27]
Clinical trial, II NSCLC IIIB/IV Erlotinib vs. Paclitaxel/Carboplatin in
patients with a performance status (PS) of 2
secondary No sign. differences. EORTC QLQ-LC13
Maione P et al.
(2005) [28]
Clinical trial, III NSCLC IIIB/
IV
The prediction of pretreated QoL on the
survival of elderly NSCLC patients
treated with chemotherapy
primary Pretreatments global QoL has a sign. prognostic
value for survival of elderly patients with
advanced NSCLC treated with chemotherapy.
EORTC QLQ-C30,-LC13
McQuellon R P
et al. (2002) [29]
Clinical trial, III NSCLC,
SCLC
Megestrol Acetate vs. placebo in patients
undergoing radiation therapy
primary No sign. difference in overall QoL. FACT-General, FACT-L
Mohan A et al.
(2008) [30]
QoL-study NSCLC III/IV Cisplatin/Etoposide primary Sign. improvement in cough, shortness of breath,
pain but not in QoL.
WHOQOL-BREF, Hindi
Moinpour CM
et al. (2002) [31]
Clinical trial, III NSCLC IIIB/
IV
Cisplatin/Vinorelbine vs. Carboplatin/Paclitaxel secondary No sign. difference in QoL. FACT-L
Morita S et al.
(2003) [32]
Clinical trial, III NSCLC IIIB/
IV
Cisplatin/Irinotecan vs. Cisplatin/Vindesine
vs. Irinotecan
secondary Clinical parameters have a sign. effect on QoL
in patients undergoing chemotherapy.
QoL questionnaire for cancer
patients treated with
anti-cancer drugs (QOL-ACD)
Movsas B et al.
(2005) [33]
Clinical trial NSCLC II/IIIA/B Paclitaxel/Carboplatin with or
without Amifostine
secondary QoL was not sign. different between the arms. EORTC QLQ-C30,-LC13
Mu XL et al.
(2004) [34]
“Compassionate-Use”
NSCLC III/IV
Gefitinib primary Symptom relief and improvement in QoL. EORTC QLQ-C30,-LC13
Natale RB
(2004) [35]
Clinical trial, II NSCLC
advanced
Different treatment dosages Gefitinib secondary Improvements in symptoms and QoL. FACT-L
O’Brian MER et al.
(2006) [36]
Clinical trialSCLC Best Supportive Care with or without
Topotecan in patients with relapsed SCLC
secondary Slower QoL deterioration and greater
symptom control.
Patient self assessment similar
to the LCSS, EQ-5D
Paccagnella A
et al. (2004) [37]
Clinical trial, III NSCLC IIIB/
IV
Mitomycin/Vinblastine/Cisplatin vs.
Mitomycin/Vinblastine/Carboplatin
primary Spitzer’s questionnaire showed an improved
QoL index for Carboplatin.
Spitzer-Index, EORTC
QLQ-C30,-LC13
Pijls-Johannesma
M et al. (2009) [38]
QoL-study NSCLC I – III,
SCLC
Radiotherapy with or without chemotherapy primary Overall QoL increases back to baseline within
3 months.
EORTC QLQ-C30,-LC13
Reck M et al.
(2006) [39]
Clinical trial, III SCLC Paclitaxel/Carboplatin/Etoposide phosphate vs.
Carboplatin/Etoposide phosphate/Vincristine
primary Paclitaxel-containing regimen sign. improved
QoL parameters like global overall QoL.
EORTC QLQ-C30
Sarna L et al.
(2008) [40]
Clinical trial, III NSCLC II/III Paclitaxel/Carboplatin with or without
Amifostin
primary QoL was not sign. different between the arms. EORTC QLQ-C30,-LC13
Clinical trial, III NSCLC III primary EORTC QLQ-C30,-LC13
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Table 2 Identified literature overview (Continued)
Schumacher A et al.
(2003) [41]
Cisplatin/Etoposide followed by either surgery
before radiotherapy or radio-chemotherapy
before surgery
On QoL no sign. effect was found in or
between the two treatments.
Sekine I et al.
(2009) [42]
Clinical trial, III NSCLC IIIB/
IV
Gefitinib vs. Docetaxel secondary Gefitinib improved aspects of QoL
over Docetaxel.
FACT-L
Sirisinha T et al.
(2005) [43]
N/A NSCLC II-IV Docetaxel after failure with platinum-based
chemotherapy
secondary No negative impact on overall QoL. FACT-L
Thatcher N
et al. (2005) [44]
Clinical trial SCLC Ifosfamide/Carboplatin/Etoposid/Vincristine vs.
standard chemotherapy
primary No sign. differences regarding QoL. Rotterdam Symptom Checklist,
HADS, EORTC QLQ-C30,-LC13
Tian JH et al.
(2010) [45]
Clinical trial NSCLC IIIB/IV Chemotherapy vs. “Feiji Recipe” vs.
Chemotherapy/“Feiji Recipe”
primary "Feiji Recipe" alone or in combination
might partially improve QoL.
EORTC QLQ-C30
Vilmar A et al.
(2010) [46]
Clinical trial, III NSCLC III/IV Chemotherapy; Determination of
biomarker ERCC1
primary QoL deteriorated sign. among
survival-favourable ERCC1-neg. patients
EORTC QLQ-C30,-LC13
von Plessen C
et al. (2006) [47]
Clinical trial NSCLC IIIB/IV Optimal duration of palliative Carboplatin
with Vinorelbine treatment
primary No sign. differences between the arms. EORTC QLQ-C30,-LC13
Wu WY et al.
(2006) [48]
QoL-study NSCLC IIIB/IV Gemcitabine/Cisplatin with or without
Shenfu Injektion
primary Shengfu Injektion could improve QoL in
patients with Gemcitabine/Cisplatin treatment.
Functional Living
Index-Cancer, EORTC QLQ-C30
Zhang XT et al.
(2005) [49]
“Compassionate-Use”
NSCLC III/IV
Gefitinib primary Symptom relief and improvement in QoL. EORTC QLQ-C30,-LC13
EORTC QLQ -C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (30 Items); EORTC QLQ-LC13 = EORTC QLQ-Lung Cancer (13 Items); EQ-5D = EuroQol-5 Dimensions;
FACT-G = Functional Assessment of Cancer Therapy-General; FACT-L = FACT-Lung; HADS = Hospital Anxiety and Depression Scale; LCSS = Lung Cancer Symptom Scale; NSCLC = Non-Small Cell Lung Cancer;
QoL=Quality of Life, SCLC = Small Cell Lung Cancer; sign.= significant; WHOQOL = World Health Organization Quality of Life assessment instrument.
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http://www.healtheconomicsreview.com/content/3/1/15in stages III/IV. Two studies include patients with small
cell lung cancer (SCLC) in all stages. In three studies both
NSCLC and SCLC patients entered. Mainly platinum-
based drug combinations are trialed. Eight studies in-
vestigate EGFR inhibitors: 6 studies examine the effect
of gefitinib, 2 the effect of erlotinib.
Identified health-related quality of life (HRQoL)
questionnaires
Overall, 17 different measurement instruments were
identified within the included studies (see Figure 2). Five
of them are generic, such as the EQ-5D of the EuroQol
group or the Spitzer Quality of Life Index. Another 5
instruments are cancer-specific, like the general quality
of life questionnaires of the European Organization for
Research and Treatment of Cancer (EORTC QLQ-C30)
or the FACT-G (Functional Assessment of Cancer
Therapy-General) questionnaire. Four instruments are lung
cancer-specific, like the lung cancer modules of the EORTC
and the FACT-L (Lung) questionnaire as well as the Lung
Cancer Symptom Scale (LCSS). The remaining 3 ques-
tionnaires are symptom-specific, such as the HospitalFigure 2 Frequency of used HRQoL-questionnaires.Anxiety and Depression Scale (HADS) or the Brief Pain
Index (BPI).
The most frequently used instrument is the EORTC
QLQ-C30 (n = 29), a general questionnaire designed for
(self- or interviewer administration) use in cancer patient
populations [50]. This 30-item multi-dimensional ques-
tionnaire is available in over 60 languages and contains 4
domains (functional and symptom scales, global quality of
life, and single items) requested by 4-point Likert or visual
analogue scales. Its lung cancer specific module LC13
(13 additional items) is also used widely.
The FACT questionnaires are less frequently used
(n = 8). Here, the FACT-G (General) contains 27
multi-dimensional items (physical, emotional, social
and functional well-being) scored on 4-point scales
[51], available in more than 50 languages. The lung
cancer questionnaire (FACT-L) is a combination of the
FACT-G and disease specific items (in total 37). Further in-
formation about the questionnaires as well as comparisons
of possible instruments for lung cancer patients can e.g. be
found on PROQOLID [52], and in Liu et al.[3], Camps
et al.[4] or Damm et al. [53].
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ments were used, mostly cancer and lung cancer-specific
ones (see Table 2). In 23 studies (53%) the EORTC QLQ-
C30 in conjunction with the LC13 module was used. Five
studies combined disease-specific (cancer or lung cancer)
questionnaires with generic instruments; two times the
EQ-5D was applied.Content-related results of the identified literature
Because of the different study populations and treatment
regimes it is not possible to compare all the different
studies in terms of HRQoL (see Table 2). However we
tried to arrange some groups of HRQoL findings.
A majority of the included trials comparing various
agent regimes shows no significant differences be-
tween treatment arms [13,15,21,29,31,41,44,47]. An-
other group of studies report cautious assumptions
of HRQoL improvements [18,22,37]. Solely, Belani
et al. and Reck et al. could show HRQoL-regarded
superiority for paclitaxel or docetaxel containing
regimes compared to vincristine or vinorelbine/cis-
platin [9,39].
With regard to the EGFR inhibitors Gelibter et al.,
Mu et al., and Zhang et al. all demonstrated symptom
relief and improvement in HRQoL by the compassionate
use of gefitinib in highly advanced NSCLC patients
[20,34,49]. Cella et al. and Natale et al. reported on
HRQoL improvements after the administration of
gefitinib, compared to baseline in heavily pretreated pa-
tients and the correlation of these improvements to the
tumour response [16,35].
In terms of erlotinib, Lilenbaum et al. could not show
significant improvements in progression-free survival,
median survival, and HRQoL in comparison to stand-
ard chemotherapy [27]. Bezjak et al. showed significant
improvements in HRQoL, if erlotinib was given as second
line treatment after chemotherapy [11].
Three studies investigated the application of cyto-
static agents in elderly patients. Bianco et al. showed
improvements in HRQoL for gemcitabine as a single
agent therapy [12], Hensing et al. demonstrated that
the application of carboplatin/paclitaxel has no sig-
nificantly different impact on HRQoL between youn-
ger (<70 years) and elderly patients [24]. LeCaer et al.
showed stable HRQoL values during docetaxel monother-
apy [25].
Movsas et al. and Sarna et al. reported no significant
HRQoL differences between treatment regimes in combin-
ation with or without amifostine [33,40].
A last group of studies showed influences on HRQoL
values, e.g. age and baseline quality of life (QoL) [Bozcuk
et al.], the cognitive function [Chen], as well as clinical
parameters Morita et al. [14,17,32].Discussion
The present study continues the work of previous reviews
like the one of Liu et al. for the indication of lung cancer [3].
HRQoL measurement obtains a twofold meaning in
the field of lung cancer medication. This is due to the
often severe (toxic) therapeutic side effects, but also
because of the high demand for symptom palliation.
However, the measurement of HRQoL in respective trials
is still not consistent and barely comparable [2-4].
By far the most frequently used questionnaire is the
EORTC QLQ-C30 in conjunction with the lung cancer-
specific module LC13. In comparison, even other lung
cancer specific instruments like the FACT-L and the
lung cancer symptom scale (LCSS) are only used in
relatively few studies [4]. The same applies to the generic
instruments. Especially the EQ-5D, which is relevant
for health economic evaluations, is rarely used. How-
ever, it turns out that, besides the dominant EORTC
instruments, a broad portfolio of other questionnaires
is applied in different varieties and combinations.
This also includes highly sensitive symptom-specific
questionnaires. The comparability of these study results
thereby is restricted.
A comparison with further literature shows that our
results are e.g. in line with Liu et al. and also with Salvo
et al. [3,54]. The latter conducted a literature review,
published in 2009, searching for quality of life measure-
ment instruments in cancer patients receiving palliative
radiotherapy for symptomatic lung cancer. The authors
also concluded that EORTC QLQ-C30 was the most
commonly used questionnaire (in 13 of 20 trials). Of
those 13 studies, 8 also used the LC13 module. The
FACT-L was used in only 2 of the included 20 trials.
Salvo et al. furthermore considered that HRQoL was of
low priority as an endpoint and that measures created
for lung cancer patients were underused.
Montazeri et al. identified the EORTC QLQ-C30 and
the EORTC QLQ-LC13 as the most sophisticated ques-
tionnaires, compared to 50 other instruments to measure
the HRQoL in lung cancer patients [55]. This might be
one reason for their common use. Another might be the
specific symptoms of the lung cancer disease. Moreover,
the disease-specific, ordinal scaled profile instruments
allow a separate evaluation of therapeutic effects for
various dimensions. However, for the comparing of
costs and effectiveness in health economic evaluations,
an index value is required.
Many of the identified questionnaires allow for the
aggregation into one index value, but this is by simply
summarising the dimension values. Thus, it is based on
an arbitrary weighting of individual aspects of quality of
life. Such a value is met with the criticism of being
barely interpretable and informative. In addition, the or-
dinal scaling of the items is inadequate for the economic
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whether significant improvements in HRQoL can be
achieved in the situation of relatively expensive therapy.
The EQ-5D is the only identified questionnaire in this
study that measures the quality of life in a cardinal index
value and thus meets the requirements of cost-utility
analyzes. However, as a generic instrument, the EQ-5D
is limited by the disadvantage of a relatively low sensiti-
vity in the measurement of small changes in quality of
life. This is probably one reason for its relatively rare use
in lung cancer studies.
Nevertheless, there are ways in which the identified
questionnaires could be used in economic evaluations.
One possibility is to transform the most widely used
questionnaires EORTC QLQ-C30 and QLQ-LC13 into
preference-based versions, similar to the development of
the SF-36. This was already considered by the EORTC in
the early 90s [50].
In what follows, we highlight some limitations with
respect to our research strategy and the results of
literature reviews in general. One major limitation of
literature reviews is the publication bias. We only consid-
ered published full-text study results, no short reports, no
conference presentations or study protocols. A comparison
with the database clinicaltrials.gov might be a more
complete research approach.
Furthermore the restriction of the publication time
period might also be a limitation. However, we wanted
to analyse the actual situation. In addition, the develop-
ments in the fields of HRQoL questionnaires could lead
to problems of interpretation.
Our literature search was performed in the Pubmed
database only. This is another limitation of our work.
Nevertheless, we tried to limit this bias by conducting
an additional manual search.
Conclusions
The cancer-specific EORTC QLQ-C30 with the lung
cancer-specific LC13 module are the dominant instru-
ments in HRQoL measurement in lung cancer studies.
Besides these instruments, a broad spectrum of other
questionnaires is used in different varieties and combi-
nations. Only a small number of studies used generic
instruments like the EQ-5D.
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